Nataliya Agafonova
Förmögenhet: 185 013 $ per 2026-09-30
Förmögenhet: 185 013 $ per 2026-09-30
Dr. Nataliya Agafonova is a Chief Medical Officer at Longeveron, Inc. Dr. Agafonova was previously employed as a Senior Medical Director by Bristol Myers Squibb Co. and a Senior Medical Director by Otsuka Pharmaceutical Development & Commercialization, Inc. She received her doctorate degree from Bogomolets National Medical University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
LONGEVERON INC. CLASS A 2,26 % | 2026-10-01 | 68 778 ( 2,26 % ) | 185 013 $ | 2026-09-30 |
| Företag | Position | Start |
|---|---|---|
| LONGEVERON INC. | Teknisk/Vetenskaplig/F&U Direktör | 2023-07-01 |
| Företag | Position | Slut |
|---|---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Teknisk/Vetenskaplig/F&U Direktör | 2023-06-01 |
| BRISTOL-MYERS SQUIBB COMPANY | Teknisk/Vetenskaplig/F&U Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Bogomolets National Medical University
Bogomolets National Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Longeveron, Inc.
Longeveron, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cellular therapies for aging-related and life-threatening conditions | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån